Gl
Gloria Biosciences
Suzhou CNFounded 2018100 employees
Private CapbiotechPrivateOncology
Platform: Anti-CD73
Market Cap
N/A
All Drugs
4
Clinical Trials
7
Failed / Terminated
3
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| GLO-4270 | GLO-4270 | Phase 1 | 2 | CFTR | DravetCTCL | ||
| GLO-7885 | GLO-7885 | Phase 1 | 2 | IL-23 | Huntington's | ||
| GLO-9656 | GLO-9656 | NDA/BLA | 1 | GPRC5D | RA | ||
| Rimafotisoran | GLO-9517 | Phase 2/3 | 2 | FcRn | HS |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (5)